Dashboard
Poor Management Efficiency with a low ROCE of 5.02%
- The company has been able to generate a Return on Capital Employed (avg) of 5.02% signifying low profitability per unit of total capital (equity and debt)
High Debt Company with a Debt to Equity ratio (avg) at times
Poor long term growth as Net Sales has grown by an annual rate of -21.59% and Operating profit at -191.38% over the last 5 years
With a fall in Net Profit of -94.85%, the company declared Very Negative results in Mar 25
Stock DNA
Pharmaceuticals & Biotechnology
CNY 953 Million (Small Cap)
NA (Loss Making)
NA
2.13%
0.02
-15.44%
0.83
Total Returns (Price + Dividend) 
Zhejiang Wecome Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Zhejiang Wecome Pharmaceutical Hits Day High with 9.83% Surge
Zhejiang Wecome Pharmaceutical Co., Ltd. has seen a notable increase in stock performance, achieving significant gains recently. The company has outperformed the China Shanghai Composite over the past week and year, despite facing challenges such as low profitability and a high debt-to-equity ratio.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
QoQ Growth in quarter ended Mar 2025 is 448.47% vs -127.84% in Dec 2024
QoQ Growth in quarter ended Mar 2025 is 94.93% vs -734.11% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -34.31% vs -2.58% in Dec 2023
YoY Growth in year ended Dec 2024 is -1,940.85% vs -114.34% in Dec 2023






